Kolexia
Gravis-Mescam Gwenaelle Oncologie médicale
Gravis-Mescam Gwenaelle
Oncologie médicale
Centre Paoli-Calmettes
Marseille, France
511 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Carcinomes Néphrocarcinome Métastase tumorale Tumeurs prostatiques résistantes à la castration Tumeurs du rein Tumeurs de la vessie urinaire Carcinome transitionnel Tumeurs embryonnaires et germinales

Collaborateurs

Voir plus
Flechon Aude
Flechon Aude
Centre Léon-Bérard, Lyon, France
Fizazi Karim
Fizazi Karim
Gustave-Roussy, Villejuif, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France
Laguerre Brigitte
Laguerre Brigitte
Centre Eugène Marquis, Rennes, France

Industries

Voir plus
Ipsen
19 collaboration(s)
Dernière en 2023
Advanced Accelerator Applications
8 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023
Pfizer
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
BISCAY: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Essai Clinique (AstraZeneca)   11 mars 2024
CheckMate 9KD: A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Essai Clinique (BMS)   01 mars 2024
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
ESMO open   23 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors: A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Essai Clinique (Unicancer)   01 février 2024
PAXIPEM: Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Essai Clinique (Merck & Co.)   18 janvier 2024
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.
European journal of cancer (Oxford, England : 1990)   15 janvier 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   12 janvier 2024